Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / American Depositary Shares, each representing 6 Ordinary Shares
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
148,301,336
-
Share change
-
+3,604,402
-
Total reported value
-
$115,679,142
-
Put/Call ratio
-
0%
-
Price per share
-
$0.78
-
Number of holders
-
77
-
Value change
-
+$2,660,882
-
Number of buys
-
21
-
Number of sells
-
41
Institutional Holders of ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) as of Q3 2023
As of 30 Sep 2023,
ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) was held by
77 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
148,301,336 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, BAILLIE GIFFORD & CO, NEA Management Company, LLC, BAKER BROS. ADVISORS LP, Long Focus Capital Management, LLC, PFM Health Sciences, LP, MPM ASSET MANAGEMENT LLC, TANG CAPITAL MANAGEMENT LLC, MPM BIOIMPACT LLC, and BANK OF AMERICA CORP /DE/.
This page lists
77
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.